Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Tuesday, June 26, 2012

Dr. Elizabeth Shephard's presentation: FMO3 - a protein that can multi-task

halitosis researchWe are currently working on providing you with Dr. Elizabeth Shephard's powerpoint presentation that she created specifically for the MEBO Conference part of our Miami Beach Meetup 2012. Meanwhile, until we are able to post this in this blog, I would like to offer you a link to it, and a link for you to download FREE QuickTime 7. Please note that QuickTime7 is free, and if you are asked to pay, then you are not in the right place. A web-embedded version of this presentation will be available in several days for me to be able to post it in this blog. Once you have downloaded QuickTime 7, you can run Dr. Shephard's powerpoint presentation using the following link:

This most valuable presentation of data highlights the dangers of certain drugs, including pesticide and psychiatric drugs, for example, for persons who have deficient metabolic clearance. Among those would be persons with FMO3 compromised systems.

Please note, that Dr. Shephard is excited with the new field of genetics called "Pharmacogenetics" which deals with how our genes influence the way we handle a drug. Pharmacogenetics is "Personalized Medicine..." and the focus treatment is "if we understand a person's genetics, can we tailor their drug treatment to get them the best response to their particular drugs."

Dr. Shephard gives us a "very short list" as examples of some FMO3 drug substrates more commonly used, including anaesthetics, a variety of anti-inflammatory (throat lozenges and sprays), anti-psychotic, and neuronal stimulant, such as nicotine. She refers to a study that has proven the inability or compromised ability of people with TMAU to be metabolize Benzydamine.

In addition, she explains how "Many drugs are metabolized by more than one enzyme" including CYPs (P450s).

I highly recommend that all persons, without exception, that suffer from any type of body odor or halitosis condition, study her presentation. All sufferers need to observe and be aware of any adverse reaction to any medication consumed, and to immediately inform their physician.

Dr. Shephard also tells us,

One thing to remember is that many people have unpleasant effects from antipsychotics and antidepressants and this may not be due to changes in FMO3.

This presentation will be put up in this blog as soon as possible.


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

Please use your credit card to make your donation to MEBO.

Subscribe for latest posts : Enter your email address:

Delivered by FeedBurner

A EURORDIS and NORD Member Organization


Post a Comment